menu
    • menu
    [{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Renexxion","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Naronapride","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Falk Pharma \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Kynos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"KNS366","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Dr. Falk Pharma \/ Dr. Falk Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Falk Pharma \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Termination","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Dr. Falk Pharma \/ Dr. Falk Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Falk Pharma \/ Dr. Falk Pharma"},{"orgOrder":0,"company":"Dr. Falk Pharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dr. Falk Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Dr. Falk Pharma \/ Dr. Falk Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dr. Falk Pharma \/ Dr. Falk Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Dr. Falk Pharma

    Menu

    Dr. Falk Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KNS366

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I

                            Recipient : Kynos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Dr. Falk Pharma Acquires Kynos, Adds Acute Pancreatitis Focus

                            Details : Through the acquisition, Dr. Falk Pharma will add KNS366 to its R&D pipeline and further explore its potential in upcoming clinical trials for the treatment of acute pancreatitis.

                            Product Name : KNS366

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 29, 2024

                            Lead Product(s) : KNS366

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I

                            Recipient : Kynos Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naronapride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Renexxion

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Renexxion and Dr. Falk Expand Phase 2b Study of Naronapride in Gastroparesis

                            Details : ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4R agonist and D2R antagonist. It is being evaluated for the treatment of Gastroparesis.

                            Product Name : ATI 7505

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 13, 2024

                            Lead Product(s) : Naronapride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Renexxion

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma

                            Details : Cosmo terminates mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX (Rifamycin Sodium) in the EU and other selective countries.

                            Product Name : Rifamycin SV MMX

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 04, 2023

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed

                            Dr. Falk Pharma

                            Germany arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cosmo Expands Agreement with Dr. Falk Pharma for Rifamycin SV MMX

                            Details : Cosmo expanded its existing license agreement with Dr. Falk Pharma to include Rifamycin SV MMX (Rifamycin Sodium) in the new 600mg formulation currently tested in the IBS-D indication.

                            Product Name : Rifamycin SV MMX

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            November 19, 2020

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth